Eton Pharmaceuticals, Inc. ETON Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| License | $0-100% | $0— | $0-100% | $0— | $3.29M— | |
| Product Sales And Royalties | $24.27M+73.4% | $21.28M+82.7% | $22.46M+129% | $18.93M+109% | $14M+75.7% | |
| Cost of Goods Sold by Product | ||||||
| License | $0-100% | $0— | $0-100% | $0— | $825K— | |
| Product Sales And Royalties | $9.53M+44.5% | $8.18M+58.2% | $14.6M+289% | $7M+103% | $6.6M+123% | |
| Other Commitment by Product | ||||||
| Hemangeol | $700K— | —— | —— | —— | —— | |
| Uridine Triacetate | $1M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eton Pharmaceuticals, Inc. break its business down?
- Eton Pharmaceuticals, Inc. (ETON) reports revenue by product across 2 parts — License and Product Sales And Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Eton Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eton Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
